Metastatic angiosarcoma is one of the most challenging diagnoses in cancer care. When this rare and aggressive tumor spreads from its original location to distant parts of the body, treatment shifts from trying to cure the disease to managing symptoms, slowing its spread, and improving the quality of everyday life. Understanding the treatment options—both those used in everyday practice and those being explored in clinical trials—can help patients and their families navigate this difficult journey.

Understanding Treatment Goals When Cancer Has Spread

When angiosarcoma has already traveled to other organs, the focus of treatment changes significantly. At this stage, the disease is considered metastatic, meaning cancer cells have moved beyond where they first appeared and formed new tumors in distant locations such as the lungs, liver, bones, or brain. Surgery to remove all cancer is usually not possible once the disease has spread this widely. Instead, doctors aim to control the growth of cancer cells, ease troubling symptoms like pain or fatigue, and help patients maintain their ability to do the things they value in daily life.^[1][4]

The treatment plan for metastatic angiosarcoma depends on many personal factors. These include where the cancer has spread, how many sites are affected, how fast the tumors are growing, and the person’s overall health and strength. Age, other medical conditions, and personal preferences about treatment intensity all play a role. Because angiosarcoma is so rare—representing only about 1 to 2 percent of all soft tissue sarcomas—there is no single “standard” roadmap that works for everyone. Instead, care is tailored to each patient’s unique situation.^[1][10]

Medical guidelines recommend that patients with metastatic angiosarcoma receive care from a team of specialists. This often includes medical oncologists who manage chemotherapy, radiation oncologists who direct radiation treatments, and other experts who help with symptom management and supportive care. Regular communication within this team helps ensure that every aspect of the disease is being addressed, from tumor control to quality of life.^[10][15]

Standard Treatment Options for Metastatic Angiosarcoma

The backbone of treatment for metastatic angiosarcoma is chemotherapy—the use of powerful drugs that circulate through the bloodstream to attack cancer cells wherever they may be in the body. Chemotherapy cannot cure metastatic angiosarcoma, but it can slow tumor growth, shrink tumors, and relieve symptoms. It is considered the preferred treatment option for patients with advanced or metastatic disease.^[4][10]

Taxane-Based Chemotherapy

Among all chemotherapy drugs, paclitaxel stands out as particularly effective against angiosarcoma. This drug belongs to a class called taxanes, which work by disrupting the way cancer cells divide and grow. Paclitaxel is usually given once a week through an intravenous (IV) infusion. Research has shown that angiosarcoma is highly sensitive to taxanes, and paclitaxel has demonstrated good results even in patients whose disease has already been treated with other drugs.^[11][12]

National treatment guidelines list paclitaxel as a preferred first-line option for metastatic angiosarcoma. The drug is generally well tolerated, though side effects can include fatigue, numbness or tingling in the hands and feet (called peripheral neuropathy), hair loss, and changes in blood cell counts that can increase the risk of infection or bleeding. Close monitoring by the medical team helps manage these effects.^[11][12]

Anthracycline-Based Chemotherapy

Another group of drugs commonly used for metastatic angiosarcoma are the anthracyclines. The most important drug in this class is doxorubicin, which damages the DNA inside cancer cells, preventing them from multiplying. Doxorubicin can be used alone or combined with other drugs such as dacarbazine, ifosfamide, or epirubicin. These combination regimens aim to attack cancer cells through multiple mechanisms at once, potentially increasing effectiveness.^[11][12]

Doxorubicin is a powerful drug, but it carries significant side effects. One of the most serious is damage to the heart muscle, which can occur if the total dose over time becomes too high. Other common side effects include nausea, vomiting, mouth sores, fatigue, and lowered blood counts. A special formulation called liposomal doxorubicin, where the drug is enclosed in tiny fat particles, may cause fewer side effects while maintaining effectiveness.^[11][12]

Gemcitabine-Based Combinations

The drug gemcitabine is another option for treating metastatic angiosarcoma. It is usually combined with other chemotherapy drugs such as docetaxel (another taxane), vinorelbine, or dacarbazine. These combinations are recommended in clinical guidelines and are used when first-line treatments stop working or when a different approach is needed.^[11][12]

Gemcitabine works by interfering with the building blocks of DNA, making it harder for cancer cells to copy themselves. Side effects can include fatigue, low blood counts, flu-like symptoms, and shortness of breath. The addition of a partner drug often enhances effectiveness but can also increase side effects, so careful monitoring is essential.^[11]

Radiation Therapy

While chemotherapy is the main systemic treatment, radiation therapy also plays an important role in managing metastatic angiosarcoma. Radiation uses high-energy beams to destroy cancer cells in a specific area. It is often used for palliative care, meaning its goal is to relieve symptoms rather than cure the disease. For example, radiation can shrink tumors that are causing pain, bleeding, or pressure on nearby organs.^[4][12]

Studies have shown that radiation treatment is an independent predictor of longer survival in patients with metastatic angiosarcoma. It can be used alongside chemotherapy or on its own, depending on the situation. Side effects depend on where the radiation is directed and may include skin changes, fatigue, and irritation of nearby tissues.^[4]

Surgery in Metastatic Disease

Surgery is generally not a curative option once angiosarcoma has spread to multiple sites. However, in certain carefully selected cases, surgery may still be used. For example, if a patient has only one or two small metastatic tumors and is otherwise healthy, removing those tumors might provide some benefit. Surgery can also be used to relieve specific symptoms, such as removing a tumor that is blocking the intestine or causing severe pain.^[4][12]

Research from large patient databases shows that surgery did not prolong survival in most patients with metastatic angiosarcoma. This finding reinforces that chemotherapy remains the cornerstone of treatment for advanced disease.^[4]

Treatment Approaches Being Explored in Clinical Trials

Because standard chemotherapy has limited effectiveness and metastatic angiosarcoma remains extremely difficult to treat, researchers are actively studying new drugs and treatment strategies in clinical trials. These trials test whether experimental therapies are safe and whether they work better than current options. Participation in a clinical trial can give patients access to cutting-edge treatments that are not yet widely available.^[10][15]

Targeted Therapies Against Blood Vessel Growth

Angiosarcoma originates from the cells lining blood vessels, so it makes sense that drugs targeting the growth of new blood vessels might be effective. These drugs, called angiogenesis inhibitors, work by blocking signals that tumors use to create their own blood supply. Without a steady supply of oxygen and nutrients from blood vessels, tumors may struggle to grow.^[10][15]

One drug being studied in this category is pazopanib. Pazopanib blocks proteins called vascular endothelial growth factor receptors (VEGFRs), which play a key role in forming new blood vessels. In a retrospective study of patients with advanced vascular sarcomas, including angiosarcoma, who had already received standard chemotherapy, 8 out of 40 angiosarcoma patients responded to pazopanib. The median time before the disease worsened was 3 months, and median overall survival was nearly 10 months. While these results are modest, they suggest that some patients may benefit from this approach, particularly those whose tumors have genetic changes affecting vascular signaling.^[11]

Other angiogenesis inhibitors, such as sorafenib, have also been explored. In one case report, a patient with angiosarcoma whose tumor had amplification of the VEGFR gene did not respond to sorafenib but had an exceptional response to pazopanib. This highlights the importance of understanding the genetic makeup of each individual’s tumor to guide treatment choices.^[11]

Immunotherapy: Harnessing the Immune System

One of the most exciting areas of cancer research is immunotherapy—treatments that help the body’s own immune system recognize and attack cancer cells. A type of immunotherapy called checkpoint inhibitors has shown remarkable success in cancers like melanoma and lung cancer. These drugs work by blocking proteins such as PD-1 or PD-L1, which cancer cells use to hide from the immune system.^[13][16]

Although checkpoint inhibitors are not yet approved specifically for angiosarcoma, there have been promising case reports. One notable case involved a 63-year-old man with angiosarcoma of the nose that had spread to his liver. After multiple treatments including surgery, chemotherapy, and radioembolization, his disease continued to progress. His tumor was found to express PD-L1, a marker suggesting it might respond to immunotherapy. He was treated with pembrolizumab, a drug that blocks PD-1, given every three weeks for 13 cycles. His liver tumors shrank markedly, and no new facial lesions appeared. Even after stopping treatment due to side effects (hepatitis, which was managed with steroids), he remained free of new or worsening disease for 8 months.^[13]

This case and others like it suggest that immunotherapy may represent an exciting new direction for angiosarcoma treatment, especially for tumors that express PD-L1 or have high tumor mutation burden (many genetic changes, which can make tumors more visible to the immune system). Research has shown that angiosarcomas of the head, neck, face, and scalp often have a high mutation burden and a pattern of DNA damage linked to ultraviolet (UV) light exposure, suggesting these tumors might be particularly responsive to immune checkpoint inhibitors.^[13][16]

Clinical trials are ongoing to test whether checkpoint inhibitors can improve outcomes for patients with metastatic angiosarcoma. Patients interested in immunotherapy should ask their doctors whether they might be eligible for such trials.^[16]

Combination Approaches with Propranolol

An intriguing experimental treatment involves combining propranolol, a common blood pressure medication that blocks certain receptors on blood vessels, with low-dose chemotherapy drugs like vinblastine and methotrexate. This approach is called metronomic chemotherapy, where drugs are given in small, frequent doses rather than large, intermittent ones. The idea is to disrupt the blood supply to tumors while minimizing side effects.^[11][23]

In a small study of seven patients with advanced angiosarcoma, all patients responded to the combination of propranolol (40 mg twice daily) and weekly vinblastine and methotrexate. One patient had a complete response, meaning all signs of cancer disappeared, and three had very good partial responses. Median survival was 16 months. Based on these encouraging results, propranolol was granted orphan drug status in Europe for soft tissue sarcoma, and further research is underway.^[11][23]

Retrospective studies have also shown that patients with metastatic angiosarcoma who happened to be taking nonselective beta-blockers (drugs like propranolol) for other medical reasons had longer progression-free and overall survival compared to those not taking these drugs. This has sparked interest in conducting larger, controlled trials to determine whether adding propranolol to standard chemotherapy improves outcomes.^[11]

Gene Therapy and Molecular Insights

Advances in genetic research have revealed that angiosarcoma tumors often carry mutations in specific genes, such as KDR, TP53, and PIK3CA. These genetic changes can provide clues about how the cancer grows and may point toward new treatment targets. For example, tumors with PIK3CA mutations, which activate a signaling pathway involved in cell growth, might respond to drugs that block that pathway.^[10][15]

Clinical trials are exploring whether drugs that target these specific genetic alterations can be effective. This approach, called precision medicine, involves testing a patient’s tumor for genetic mutations and then choosing treatments based on those findings. While this strategy is still in early phases for angiosarcoma, it represents a promising direction for future research.^[10][15]

Understanding Clinical Trial Phases

Clinical trials are conducted in phases, each with a different purpose. Phase I trials test the safety of a new treatment in a small group of people, determining the right dose and identifying side effects. Phase II trials involve more patients and focus on whether the treatment actually works—for example, whether tumors shrink or stop growing. Phase III trials compare the new treatment to the current standard treatment in a large group of patients to see which is better. Patients with metastatic angiosarcoma may be eligible for trials in any of these phases, depending on the specific study and the patient’s condition.^[10][15]

Clinical trials for angiosarcoma are conducted at major cancer centers in the United States, Europe, and other regions. Eligibility criteria vary by trial but often include factors like the extent of disease, prior treatments received, and overall health status. Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies.^[10]

Most Common Treatment Methods

• Chemotherapy
  • Paclitaxel: A taxane drug given weekly through IV infusion, highly effective against angiosarcoma and well tolerated in most patients.
  • Doxorubicin: An anthracycline drug that damages cancer cell DNA; can be used alone or in combinations like AD (doxorubicin and dacarbazine) or AIM (doxorubicin, ifosfamide, and mesna).
  • Liposomal doxorubicin: A formulation that may reduce side effects while maintaining effectiveness.
  • Gemcitabine-based regimens: Combinations such as gemcitabine with docetaxel, vinorelbine, or dacarbazine, used when first-line treatments fail.
  • Epirubicin and ifosfamide: Alternative anthracycline and alkylating agent combinations used in some cases.
• Radiation Therapy
  • Uses high-energy beams to shrink tumors and relieve symptoms like pain or bleeding.
  • Can be used alongside chemotherapy or as a standalone palliative treatment.
  • Identified as an independent predictor of longer survival in metastatic angiosarcoma.
• Targeted Therapy
  • Pazopanib: Blocks VEGF receptors to inhibit blood vessel growth in tumors; studied in patients with vascular sarcomas after standard chemotherapy.
  • Sorafenib: Another angiogenesis inhibitor explored in angiosarcoma with mixed results.
• Immunotherapy
  • Pembrolizumab: A PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells; shown to produce responses in tumors expressing PD-L1.
  • Being explored in clinical trials, particularly for tumors with high mutation burden or UV-related DNA damage patterns.
• Combination Therapy with Propranolol
  • Propranolol (a beta-blocker) combined with metronomic vinblastine and methotrexate; all seven patients in a small study responded.
  • Propranolol granted orphan drug status in Europe for soft tissue sarcoma.
  • Retrospective data suggest nonselective beta-blockers may improve survival when added to standard treatment.
• Surgery
  • Generally not curative in metastatic disease but may be used in select cases to remove isolated metastases or relieve symptoms.

Managing Side Effects and Supporting Quality of Life

Treatment for metastatic angiosarcoma is not just about attacking cancer cells—it’s also about helping patients feel as well as possible throughout the process. Chemotherapy, radiation, and other treatments can cause a range of side effects that affect daily life. Common side effects of chemotherapy include fatigue, nausea and vomiting, loss of appetite, hair loss, mouth sores, and increased risk of infections due to low white blood cell counts. Peripheral neuropathy, causing numbness or tingling in the hands and feet, is particularly common with taxanes like paclitaxel.^[11][12]

Medical teams provide supportive care to manage these effects. Anti-nausea medications can help control vomiting. Growth factors like G-CSF can boost white blood cell production, reducing infection risk. Pain management specialists can help with chronic pain, whether from tumors pressing on tissues or from nerve damage caused by treatment. Nutritionists can advise on how to maintain adequate calorie and protein intake when appetite is poor.^[10]

Radiation therapy side effects depend on the area being treated. Skin changes, fatigue, and irritation of nearby organs are common. These effects are usually temporary and manageable with proper care.^[12]

Emotional and psychological support is equally important. A diagnosis of metastatic angiosarcoma can be overwhelming and frightening. Counseling, support groups, and palliative care teams can provide emotional support, help with decision-making, and assist with planning for the future. Palliative care focuses on relieving symptoms and improving quality of life at any stage of illness, and it can be provided alongside active cancer treatment.^[10]

Factors That Influence Survival and Treatment Response

Not all patients with metastatic angiosarcoma respond to treatment in the same way. Several factors can influence how long patients survive and how well they respond to therapy. Understanding these factors can help set realistic expectations and guide treatment planning.^[4]

One key factor is the number and location of metastatic sites. Patients with disease in just one or two organs tend to do better than those with widespread metastases. In one large study, about one-third of patients had two or more metastatic sites, and these patients generally had worse outcomes. The most common sites of metastasis are the lungs (60 percent of cases), liver (30 percent), bone (43 percent), and brain (9 percent).^[4][8]

Tumor size also matters. Tumors larger than 10 centimeters at diagnosis are associated with shorter survival compared to smaller tumors. Tumor grade, which reflects how abnormal the cancer cells look under a microscope, is another important predictor. High-grade tumors (grade IV) are more aggressive and harder to treat.^[4]

Age can influence outcomes as well. Younger patients generally tolerate treatment better and may have longer survival, though angiosarcoma affects all age groups. Overall health and fitness, often measured by what doctors call performance status, also play a role. Patients who are able to carry out normal daily activities tend to respond better to treatment than those who are bedridden or very weak.^[4]

Receiving chemotherapy is one of the most significant predictors of better outcomes. Studies consistently show that patients who receive chemotherapy live longer than those who do not, regardless of other factors. This underscores the importance of systemic treatment in metastatic angiosarcoma.^[4]

Real-World Experiences: Stories of Patients with Metastatic Angiosarcoma

While statistics and clinical data are important, real patient experiences illustrate the diverse courses this disease can take. In one published case, a 66-year-old man with scalp angiosarcoma experienced recurrence after surgery and developed multiple metastases. He was treated with a combination chemotherapy regimen consisting of cyclophosphamide, epirubicin, vincristine, and dacarbazine. He achieved a complete response, meaning all detectable cancer disappeared, with a progression-free survival time of 8 months. When the disease eventually returned, he received additional treatments including docetaxel, cisplatin, gemcitabine, radiation therapy, and anti-angiogenic therapy. Through this comprehensive, multi-pronged approach, he survived for 38 months after his initial diagnosis—far longer than the typical 6-month median survival for metastatic angiosarcoma.^[19][25]

This case highlights several important points. First, some patients do respond well to combination chemotherapy and can achieve periods where the disease is undetectable. Second, when cancer returns, additional lines of treatment can still be effective and prolong survival. Third, a comprehensive treatment strategy that combines multiple modalities—chemotherapy, radiation, targeted agents—may offer the best chance of extending life while maintaining quality of life.^[19][25]

Another case involved a patient with angiosarcoma who responded to immunotherapy after multiple other treatments had failed. These individual success stories, while not guaranteed for every patient, demonstrate that meaningful responses are possible and that ongoing research continues to uncover new options.^[13]

The Role of Specialized Centers and Multidisciplinary Care

Given the rarity and complexity of angiosarcoma, treatment at a specialized sarcoma center is strongly recommended. These centers have teams of experts who regularly treat rare cancers and are up to date on the latest research and clinical trials. A multidisciplinary team typically includes medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, nurses specialized in cancer care, social workers, and palliative care specialists.^[10][15]

At these centers, patient cases are often discussed in tumor boards, where specialists from different fields meet to review each patient’s situation and develop a coordinated treatment plan. This collaborative approach ensures that all options are considered and that the plan reflects the latest evidence and best practices.^[10][15]

Specialized centers are also more likely to offer access to clinical trials, cutting-edge diagnostic techniques (such as genetic testing of tumors), and experimental treatments. They may have experience with rare drug combinations or techniques not widely available elsewhere.^[10][15]